Given these knowledge gaps, the goals of the current study were to determine which cells of the upper airway tract express ACE2 and TMPRSS2 and test whether their expressions could be therapeutically targeted by AR inhibitors used in prostate cancer treatment. This evidence concerns the gene ACE2 and prostate cancer.